Outbreaks of Zika virus have been reported in several areas including tropical Africa, Southeast Asia and the Pacific Islands. This infectious disease can lead to microcephaly and other severe fetal brain defects, which presents a significant public health challenge. Because of this, an effective Zika vaccine is urgently needed, but there are delays in development due to a number of complexities.
Discover the role of a clinical trial vaccine lab in Zika vaccine development and how you can proactively avoid challenges along the development continuum.
Authors:
Wayne Hogrefe, Ph.D., D (ABMLI), Vice President, Vaccine unit
Paul Rhyne, Ph.D.
Complete the form below to access this insight brief
Related Insights
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
Vaccine Testing for SARS-CoV-2
ELISA and Viral Neutralization Assays
Keeping Up with the Flu: Advances in seasonal influenza vaccine development
Vaccine Laboratory Services
Combating Emerging and Re-Emerging Infectious Diseases in Clinical Trials by Harnessing Innovative Technologies
Harnessing innovative technologies for clinical trials involving emerging and re-emerging infectious diseases
Tools for better management of infectious disease clinical trials
Vaccine Testing Capabilities
End-to-end laboratory for clinical vaccine development
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
